Search Clinical Trials in the European Union

Duration
Visits
Phase
Injection
Benefits
Drugs
Locations
Clinical Specialty
841-860 of 2,120 trials

HER2-Positive Breast Cancer: Zanidatamab vs. Trastuzumab

We are studying whether zanidatamab combined with chemotherapy is more effective and safer than trastuzumab with chemotherapy for patients with metastatic HER2-positive breast cancer who have not responded to previous treatments.

Metastatic HER2-positive Breast Cancer3-6 monthsConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Autoimmune Disease: Ianalumab Delivery Methods

We are comparing two ways to deliver ianalumab to adults with autoimmune diseases. This study will help us understand how well the medication works and its safety when given in different forms.

Sjögren's DiseaseRheumatoid ArthritisSystemic Lupus Erythematosus6-12 monthsEfficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteInternal MedicineRheumatology

Cardiac Device Implantation: Local vs. Regional Anesthesia

We are comparing local anesthesia with a specific regional block to see which provides better comfort for patients undergoing cardiac device implantation. This study also looks at any side effects and the need for extra pain relief.

Implantation of Cardiac Devices1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCardiologyInternal MedicineOtolaryngology

Pancreatic Cancer: Antiplatelet Therapy Study

We are investigating if adding an antiplatelet medication to standard care can help prevent blood clots in patients with pancreatic cancer. We also want to see if it may improve survival rates.

Pancreatic Ductal Cancer6-12 monthsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteCardiologyOncology

Graft-Versus-Host Disease Prevention: CY-MET-RIC Study

We are testing two different treatment plans to see which better prevents severe graft-versus-host disease in patients receiving matched-donor transplants. This study will also evaluate overall survival and other important health outcomes.

Hematological Malignancies>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyInfectious Diseases

Vedolizumab for Children with Moderate to Severe Crohn's Disease

We are studying how well different doses of vedolizumab help children and teenagers with Crohn's disease maintain their health. The goal is to see if it can keep symptoms under control and improve their overall well-being.

Crohn's Disease1-2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementGastroenterologyPediatrics

Ulcerative Colitis and Crohn's Disease: Vedolizumab IV in Kids

We are studying the long-term safety of vedolizumab IV in children and teenagers with ulcerative colitis or Crohn's disease. This research aims to understand its effects on health and quality of life.

Active Ulcerative Colitis or Crohn's Disease>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementGastroenterology

Septic Shock: Early Use of Vasopressin

We are studying whether starting vasopressin treatment earlier helps improve kidney function in patients with septic shock. This trial aims to see if it reduces the need for kidney support and other complications in the ICU.

Septic Shock1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesInternal MedicineNephrologyPulmonology

Metastatic Uveal Melanoma: Tebentafusp Treatment

We are studying the effects of tebentafusp in patients with metastatic uveal melanoma that has spread to the liver. The goal is to see if it can help achieve complete responses and improve disease control.

Uveal Melanoma>2 yearsEfficacy phase (II)>20 visitsNo PlaceboStandard MedicinesOncology

Ovarian Stimulation for Poor Responders: CFA vs. Modified Natural Cycles

We are comparing a single cycle of a new medication with multiple natural cycles in women who may not respond well to fertility treatments. The goal is to see which method leads to better quality embryos and higher chances of pregnancy.

Subfertility3-6 monthsMonitoring phase (IV)≤5 visitsNo PlaceboInvestigational MedicinesEndocrinologyGynecology and Obstetrics

Crohn's Disease: New Treatment Target Study

We are investigating if aiming for complete healing of all bowel layers improves outcomes for patients with active Crohn's disease. This study compares different treatment strategies to see which is more effective.

Crohn's Disease1-2 yearsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesGastroenterologyInternal Medicine

TMJ Arthritis: Cortisone Injection vs. Arthrocentesis

We are comparing the effectiveness of a cortisone injection and a procedure called arthrocentesis for relieving pain in people with TMJ arthritis. We also want to see how these treatments affect mouth opening and if other factors play a role in recovery.

Temporomandibular Joint Arthritis3-6 monthsMonitoring phase (IV)No PlaceboStandard MedicinesOrthopedics and Traumatology

Primary Immune Thrombocytopenia: Belantamab Mafodotin Study

We are investigating a new treatment for adults with primary immune thrombocytopenia who have previously received other therapies. The study aims to assess the safety and effectiveness of this new drug.

Primary Immune Thrombocytopenia1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesHematology

Pulmonary Arterial Hypertension: Sotatercept Study

We are evaluating the long-term safety of sotatercept for adults with pulmonary arterial hypertension already on treatment. This study will help us understand how well it works when added to existing therapies.

Pulmonary Arterial Hypertension>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteCardiology

Advanced Solid Tumors: TransCon IL-2 β/γ Treatment Study

We are investigating the safety and tolerability of TransCon IL-2 β/γ alone and with other cancer therapies for adults with advanced solid tumors. This study aims to find the best dose and understand how it works in combination with existing treatments.

Advanced Solid Tumor Cancers>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Systemic Lupus Erythematosus: Belimumab Study

We are studying the effects of belimumab in adults with early systemic lupus erythematosus to see if it helps improve their condition and reduce steroid use.

Systemic Lupus Erythematosus>2 yearsMonitoring phase (IV)16-20 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteRheumatology

Targeted Anti-Cancer Drugs: DRUP Trial

We are studying how well existing targeted drugs work for patients with advanced cancers that have specific genetic markers. This trial aims to improve access to effective treatments and gather important data on their use.

Non-Hodgkin LymphomaAdvanced Solid TumorT-cell Prolymphocytic Leukemia3-6 monthsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Kidney Function: Non-Radioactive Measurement Methods

We are evaluating a new non-radioactive method for measuring kidney function in comparison to traditional radioactive techniques. This study aims to ensure accurate assessments while minimizing radiation exposure.

Chronic Kidney Disease3-6 monthsMonitoring phase (IV)No PlaceboStandard MedicinesCost ReimbursementInternal MedicineNephrology

Extrahepatic Cholangiocarcinoma: Durvalumab with Radiofrequency Ablation

We are studying a new treatment combining durvalumab and radiofrequency ablation for patients with bile duct cancer. The goal is to see if this combination improves effectiveness and safety compared to standard therapies.

Extrahepatic Cholangiocarcinoma>2 yearsEfficacy phase (II)>20 visitsNo PlaceboStandard MedicinesGastroenterologyOncology

Avian Influenza Vaccine: Immune Response Study

We are studying how well a new avian influenza vaccine triggers immune responses in people, especially those with prior seasonal flu vaccinations. This research aims to understand its effectiveness against various H5N1 virus strains.

Avian Influenza and Seasonal Influenza1-2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesInfectious DiseasesPulmonology